Actively Recruiting
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
Led by University Hospitals Cleveland Medical Center · Updated on 2026-04-02
56
Participants Needed
1
Research Sites
216 weeks
Total Duration
On this page
Sponsors
U
University Hospitals Cleveland Medical Center
Lead Sponsor
L
LEO Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigators propose to improve the possibility of reaching skin resolution by identifying certain markers or gene patterns that may predict patient response to certain psoriasis drugs ahead of time, thus eliminating or reducing the trial-and-error approach often employed. The ability to rule out (or in) specific therapeutics based on predictive efficacy would lead to a more personalized approach for psoriasis treatment. To do this, the investigators will be asking participants to try two different already on the market FDA-approved psoriasis drugs for 8 weeks at a time. The investigators will be monitoring participants skin for improvements as well as taking blood and skin samples at least three times. Investigators may also ask to take stool samples and/or skin swabs.
CONDITIONS
Official Title
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with plaque-type psoriasis by a board-certified dermatologist, dermatology nurse practitioner, or skin punch biopsy
- Have insurance that includes coverage for ustekinumab and at least one anti-p19 biologic (guselkumab or risankizumab)
- Have never been treated with ustekinumab, guselkumab, or risankizumab before
- Have psoriasis involving at least 10% of your body surface area at screening and baseline
- Able to provide informed consent under IRB approval procedures
You will not qualify if you...
- Pregnant, breastfeeding, or planning pregnancy from 8 weeks before to 8 weeks after the study
- Unable to provide informed consent
- Unable to obtain ustekinumab and either guselkumab or risankizumab for the trial
- Used tanning booths within 4 weeks before baseline visit
- Used topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy on lesions within 2 weeks before baseline and during trial
- Used systemic or biologic therapy within 8 weeks before baseline
- Have psoriatic arthritis or other rheumatologic diseases such as Crohn's disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Actively Recruiting
Research Team
A
Amy Johnson, MD
CONTACT
A
Amanda Davies, MBA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here